title   Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical Content   HALIFAX  Nova Scotia   BUSINESS WIRE   Appili Therapeutics Inc   TSXV  APLI   the Company or Appili   a publicly traded biopharmaceutical company focused on anti infective drug development  announced today it has signed an agreement with FUJIFILM Toyama Chemi    10174 chars  Description   HALIFAX  Nova Scotia   BUSINESS WIRE       IMV  AntibioticDeveloper  Appili Therapeutics Acquires ATI 2307  a clinical stage antifungal program From FUJIFILM Toyama Chemical 